87 related articles for article (PubMed ID: 1106918)
1. Binding of the complement intermediate C56 to zymosan in acute phase human sera.
Baker PJ; Rubin LG; Lint TF; McLeod BC; Gewurz H
Clin Exp Immunol; 1975 Apr; 20(1):113-24. PubMed ID: 1106918
[TBL] [Abstract][Full Text] [Related]
2. Inherited deficiency of the seventh component of complement associated with nephritis. Propensity to formation of C56 and related C7-consuming activity.
Nemerow GR; Gewurz H; Osofsky SG; Lint TF
J Clin Invest; 1978 Jun; 61(6):1602-10. PubMed ID: 350902
[TBL] [Abstract][Full Text] [Related]
3. Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9.
Lachmann PJ; Thompson RA
J Exp Med; 1970 Apr; 131(4):643-57. PubMed ID: 4193935
[TBL] [Abstract][Full Text] [Related]
4. Anaphylatoxin formation by contact activation of plasma. 3. Fixation of two different anaphylatoxin-forming complexes on zymosan.
Brade V; Schmidt G; Vogt W
Eur J Immunol; 1972 Apr; 2(2):180-6. PubMed ID: 4644242
[No Abstract] [Full Text] [Related]
5. Breakdown products of C 3 in human synovial fluids.
Zvaifler NJ
J Clin Invest; 1969 Aug; 48(8):1532-42. PubMed ID: 4183680
[TBL] [Abstract][Full Text] [Related]
6. The reaction of zymosan with the properdin system in normal and C4-deficienct guinea pig serum. Demonstration of C3- and C5-cleaving multi-unit enzymes, both containing factor B, and acceleration of their formation by the classical complement pathway.
Brade V; Lee GD; Nicholson A; Shin HS; Mayer MM
J Immunol; 1973 Nov; 111(5):1389-400. PubMed ID: 4795621
[No Abstract] [Full Text] [Related]
7. C3 and C5-cleaving properdin enzymes formed on zymosan incubated with human serum: the decay and the regeneration of the enzymes.
Fujita T; Takiuchi M; Matsumoto M; Nagaki K; Inai S
Int Arch Allergy Appl Immunol; 1977; 53(4):303-9. PubMed ID: 67089
[TBL] [Abstract][Full Text] [Related]
8. Binding of the pentamer/hexamer forms of mannan-binding protein to zymosan activates the proenzyme C1r2C1s2 complex, of the classical pathway of complement, without involvement of C1q.
Lu JH; Thiel S; Wiedemann H; Timpl R; Reid KB
J Immunol; 1990 Mar; 144(6):2287-94. PubMed ID: 2313094
[TBL] [Abstract][Full Text] [Related]
9. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
[TBL] [Abstract][Full Text] [Related]
10. Kinetic studies of the formation of the properdin system enzymes on zymosan: evidence that nascent C3b controls the rate of assembly.
Nicholson A; Brade V; Lee GD; Shin HS; Mayer MM
J Immunol; 1974 Mar; 112(3):1115-23. PubMed ID: 4811964
[No Abstract] [Full Text] [Related]
11. Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
Densen P; McRill CM; Ross SC
J Immunol; 1988 Dec; 141(11):3902-9. PubMed ID: 3141507
[TBL] [Abstract][Full Text] [Related]
12. The reaction of zymosan with the properdin system: isolation of purified factor D from guinea pig serum and study of its reaction characteristics.
Brade V; Nicholson A; Lee GD; Mayer MM
J Immunol; 1974 May; 112(5):1845-54. PubMed ID: 4818461
[No Abstract] [Full Text] [Related]
13. The rabbit properdin system: I. Identification of a new factor and purification of rabbit properdin.
Naff GB; Hedrick SW; Ratnoff WD; Novak MA; Smith MC; Steiner C; Todd EW
J Immunol; 1980 Jun; 124(6):2625-31. PubMed ID: 6900053
[TBL] [Abstract][Full Text] [Related]
14. C3-independent immune haemolysis: mechanism of membrane attack complex formation.
Kitamura H; Tsuboi M; Nagaki K
Immunology; 1986 Sep; 59(1):147-51. PubMed ID: 3759127
[TBL] [Abstract][Full Text] [Related]
15. The utilization of properdin in the alternate pathway of complement activation: isolation of properdin convertase.
Stitzel AE; Spitzer RE
J Immunol; 1974 Jan; 112(1):56-62. PubMed ID: 4130153
[No Abstract] [Full Text] [Related]
16. Formation of the C3-cleaving properdin enzyme on zymosan. Demonstration that factor D is replaceable by proteolytic enzymes.
Brade V; Nicholson A; Bitter-Suermann D; Hadding U
J Immunol; 1974 Dec; 113(6):1735-43. PubMed ID: 4279261
[No Abstract] [Full Text] [Related]
17. The release of C5a in complement-activated serum does not require C6.
Biesecker G; Wagner JL; Hugli TE
J Immunol; 1989 Aug; 143(4):1228-32. PubMed ID: 2545783
[TBL] [Abstract][Full Text] [Related]
18. Membrane complement receptor type three (CR3) has lectin-like properties analogous to bovine conglutinin as functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3b.
Ross GD; Cain JA; Lachmann PJ
J Immunol; 1985 May; 134(5):3307-15. PubMed ID: 2984286
[TBL] [Abstract][Full Text] [Related]
19. Anaphylatoxin formation by contact activation of plasma. II. Implication of properdin and an unknown plasma factor in activation by zymosan.
Brade V; Vogt W
Eur J Immunol; 1971 Aug; 1(4):295-300. PubMed ID: 4945686
[No Abstract] [Full Text] [Related]
20. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Jan; 116(1):1-7. PubMed ID: 1245733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
